Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Prostate Cancer. 2004 Sep;3(2):122-4.

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

Author information

  • 1University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu

Abstract

Prostate-specific antigen testing has not only led to an earlier diagnosis of prostate cancer, but also to an earlier identification of hormone-refractory prostate cancer (HRPC). Many patients identified early with HRPC may receive first-line taxane-based chemotherapy. Patients who progress after first-line chemotherapy are still quite healthy and desire further therapy. No proven treatment options exist for the second-line treatment of HRPC. Finding new agents that are active in the second-line setting and identifying relevant outcome variables and predictive pretreatment variables are crucial in improving survival and quality of life for this patient population.

PMID:
15479496
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk